<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02971722</url>
  </required_header>
  <id_info>
    <org_study_id>DFBT-JY09-1</org_study_id>
    <nct_id>NCT02971722</nct_id>
  </id_info>
  <brief_title>a Study of JY09 in Chinese Healthy Subjects</brief_title>
  <official_title>Randomized,Double-blind,Placebo-controlled,Dose-escalating Phase I,Healthy Subjects Study of JY09,a Recombinant GLP-1 Receptor Agonist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Dongfang Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Dongfang Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      JY09，is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist,constructed with
      Exendin-4 and human Immunoglobulin G2 (IgG2) Fc fragment.Preclinical studies show that JY09
      exhibit the expected GLP-1-mediated pharmacological effects on insulin secretion,glucose
      covering and islet cell recovering,as well as good tolerance and safety.JY09 has been
      approved by China food and drug administration(CFDA) to enter the clinical research
      stage(Grant number 2016L04254).This study is designed to assess the
      safety,tolerability,pharmacokinetics,pharmacodynamics and potential immunogenicity of JY09 in
      healthy Chinese volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK)</measure>
    <time_frame>Baseline through day29 of period</time_frame>
    <description>Area Under the Concentration Versus Time Curve (AUC) of JY09</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>immunogenicity</measure>
    <time_frame>Baseline through day29 of period</time_frame>
    <description>A measure of the body's immune response to JY09</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>baseline to 3 months(cohort1 and cohort 2)</time_frame>
    <description>Weight loss of subject is greater than 3 kg will be recorded as adverse events in a month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD）</measure>
    <time_frame>Baseline through day29 of period</time_frame>
    <description>Area Under the Concentration Versus Time Curve (AUC) of Glucose</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>0.3mg JY09(cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5mg JY09(cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6.0mg JY09(cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo(cohort 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.7mg JY09(cohort2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.7mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0mg JY09(cohort2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12.0mg JY09(cohort2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo(cohort 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JY09</intervention_name>
    <description>2mg/1ml/bottle</description>
    <arm_group_label>0.3mg JY09(cohort 1)</arm_group_label>
    <arm_group_label>1.5mg JY09(cohort 1)</arm_group_label>
    <arm_group_label>6.0mg JY09(cohort 1)</arm_group_label>
    <arm_group_label>0.7mg JY09(cohort2)</arm_group_label>
    <arm_group_label>3.0mg JY09(cohort2)</arm_group_label>
    <arm_group_label>12.0mg JY09(cohort2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1ml/bottle</description>
    <arm_group_label>Placebo(cohort 1)</arm_group_label>
    <arm_group_label>Placebo(cohort 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects.

          -  Male's mass is equal or greater than 50 kg, female's mass is equal or greater than 45
             kg,have a body mass index (BMI) between 18 and 28 kilograms per square meter (kg/m^2),
             inclusive.

          -  The subjects sign informed consent form voluntarily.

          -  The subjects agree to use instruments of contraception from the time of the first dose
             until 6 months after the last dose of investigational drug, avoid pregnancy make
             yourself or your mate.

          -  Participants will be able to keep good communication with investigator and comply with
             the requirements of the clinical trials

        Exclusion Criteria:

          -  Smokers,quitting time less than 3 months , or can't quit smoking during the trial.

          -  Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter
             medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to
             dosing,or being treated for a direct lower gastrointestinal or using steroids.

          -  Participation in any clinical investigation within 3 months prior to dosing

          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing

          -  Significant illness within 2 weeks prior to dosing,and investigator judge doesn't fit
             to participate in this trial.

          -  A history of clinical significance of abnormal ECG or family history of long QT
             syndrome (grandparents, parents and siblings)

          -  Have a family history of diabetes (grandparents, parents and siblings).

          -  Have a history of acute or chronic bronchial spasms(including after treatment or no
             treatment of asthma and chronic obstructive pulmonary disease )

          -  Have a history of drug allergy or atopic disease allergy(asthma, urticaria, eczema,
             dermatitis),or allergy history of trail drugs or similar drugs.

          -  Have gastrointestinal diseases,such as history of liver disease, gastrointestinal
             disease,gastrointestinal surgery (appendix removed except) or chronic pancreatitis, or
             history of idiopathic acute pancreatitis that,in the opinion of the investigator,is
             clinical significant.

          -  Have personal or family history of medullary thyroid cancer (MTC) or a hereditary
             disease that induce MTC .

          -  Have a history of immunodeficiency disease,including human immunodeficiency virus
             (HIV) antibody positive.

          -  Have a history of needlesickness that,in the opinion of the investigator,is clinical
             significant.

          -  Have an unknown cause of infection.

          -  In screening,any abnormal results of physical examination, vital
             signs,electrocardiogram (ECG) and clinical laboratory that,in the opinion of the
             investigator,is clinical significant.

          -  Hepatitis b surface antigen or hepatitis c antibody positive, or treponema pallidum
             antibody positive.

          -  Abuse of drug or alcohol within 12 months before first dosing,or in screening found
             evidence of abuse in laboratory tests.

          -  People who are pregnant, nursing mothers, or in the near future plan to be pregnant,or
             show pregnancy test positive before into group.

          -  In screening,lying position (after 3 minutes rest) systolic blood pressure outside the
             range 90 ~ 140 MMHG, or diastolic blood pressure outside the range 50-90 MMHG, or
             pulse (HR) outside the range 40 ~ 100 bpm, boundary value into the group.

          -  Have chang of weight &gt; 3 kg within 3 months by self-report.

          -  Subjects who, in the opinion of the investigator, are in any way unsuitable to
             participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://jpet.aspetjournals.org</url>
  </link>
  <link>
    <url>http://nutritionjrnl.com</url>
  </link>
  <reference>
    <citation>Thorkildsen C, Neve S, Larsen BD, Meier E, Petersen JS. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther. 2003 Nov;307(2):490-6. Epub 2003 Sep 15.</citation>
    <PMID>12975499</PMID>
  </reference>
  <reference>
    <citation>Bradley DP, Kulstad R, Schoeller DA. Exenatide and weight loss. Nutrition. 2010 Mar;26(3):243-9. doi: 10.1016/j.nut.2009.07.008. Review.</citation>
    <PMID>20152707</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2016</study_first_submitted>
  <study_first_submitted_qc>November 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2016</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GLP-1 receptor agonist</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

